News and Resources

Choose an area of interest:

Eosinophilic Asthma Epileptic Encephalopathy Company News
02.28.22

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)

Discover this News
02.25.22

Biohaven Acquires Kv7 Ion Channel Platform For The Treatment Of Epilepsy And Other Neurologic Disorders From Channel Biosciences, A Subsidiary Of Knopp Biosciences

Discover this News
10.20.21

Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Discover this News
09.07.21

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Discover this News
05.10.21

Crafting a Cure for Diabetic Neuropathic Pain, Molecule by Molecule (Published by NIH)

Discover this News
01.14.21

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Discover this News
07.08.20

Knopp Biosciences Appoints Stephen E. Butts to Board of Managers

Discover this News
12.12.19

Knopp Biosciences to Present at Piper Jaffray 31st Annual Healthcare Conference

Discover this News
12.06.19

Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer

Discover this News
1 2